Draft Document for Public Consultation: iCARDIO Alliance Global Implementation Guidelines on Ischemic Heart Disease Management 2026
Public REVIEW PERIOD extended to Sunday, 8 March 2026
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Disclaimer: The Global Implementation Guidelines (the “Documents”) represent the views of its authors. They were produced after careful consideration of the scientific and medical knowledge and the evidence and related economic issues that may impact implementation of therapies, as well as the main guidelines on the topic, available at the time of their publication. The iCARDIO Alliance, respectively its Partner Organizations and the TMA, are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the Documents and any other official recommendations or guidelines issued by other bodies in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the Documents fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. On the other hand, the Documents do not override the individual responsibility of health professionals to make the appropriate, accurate and individual decisions in consideration of each patient’s health condition. These decisions should be taken in consultation with their individual patient and, where appropriate and/or necessary, the patient’s caregiver. The Documents do not exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines, issued by the competent public health authorities that govern them. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
Authors
Ischemic heart disease (IHD) remains the leading cause of morbidity and mortality worldwide. Coronary artery disease (CAD) encompasses any pathological process capable of compromising myocardial perfusion and although numerous etiologies exist, including vasculitis, spontaneous coronary artery dissection, and coronary embolism, the majority of CAD is attributable to coronary atherosclerosis, which constitutes the focus of this document. For practical purposes, CAD is considered present when any degree of atherosclerotic involvement exceeds zero percent stenosis, recognizing that even minimal coronary atherosclerosis represents a systemic disease process with prognostic implications.
Altmetrics
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
